marathon

Showing 4 posts of 4 posts found.

money_packets

Duchenne drug poised to cost $35,000 but with major catch

May 9, 2017
Manufacturing and Production, Sales and Marketing Duchenne Muscular Dystrophy, PTC Therapeutics, marathon

For those that have not followed the story, Emflaza was successfully taken through the FDA regulatory process by Marathon as …

marathon_logo

Marathon’s major misstep shows that drug pricing debate is here to stay

February 14, 2017
Manufacturing and Production, Sales and Marketing Duchenne Muscular Dystrophy, Emflaza, marathon

Marathon Pharmaceuticals’ approval, last week, by the FDA for its treatment for Duchenne muscular dystrophy would usually have been cause …

fda2outsideweb

FDA approves first treatment for Duchenne muscular dystrophy

February 10, 2017
Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, FDA, marathon, marathon pharmaceuticals

The FDA has announced that it has approved Emflaza (deflazacort), developed by Marathon Pharmaceuticals. The treatment will arrive on the …

FDA accepts Marathon’s Duchenne drug for priority review

August 11, 2016
Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, deflazacort, marathon, marathon pharmaceuticals

Marathon Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted and granted a priority review for …

Latest content